Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138878 | 1.00 | FFAR1 (0.46) | FFAR1ALDH1A1POLBPTGER2P2RY2 | |
| SCHEMBL6138383 | 1.00 | FFAR1 (0.46) | FFAR1ALDH1A1POLBPTGER2P2RY2 | |
| SCHEMBL9307467 | 0.93 | PTGER2 (0.48) | ALDH1A1POLBPTGER2P2RY2LTB4R | |
| SCHEMBL4427857 | 0.90 | FFAR1 (0.48) | FFAR1ALDH1A1POLBMMEGABBR2 | |
| SCHEMBL2743391 | 0.90 | ALDH1A1 (0.49) | ALDH1A1POLBPTGER2P2RY2GABBR2 | |
| SCHEMBL6386223 | 0.87 | AOC3 (0.42) | FFAR1GABBR2GABBR1LMNACYP3A4 | |
| SCHEMBL10993868 | 0.87 | FFAR1 (0.49) | FFAR1PTGER2MMELTB4RLMNA | |
| SCHEMBL7115734 | 0.84 | GABBR2 (0.47) | ALDH1A1POLBGABBR2GABBR1LMNA | |
| SCHEMBL6389499 | 0.84 | FFAR1 (0.47) | FFAR1PTGER2LTB4R | |
| SCHEMBL6138447 | 0.83 | HDAC1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1215203-B1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20040214896-A1 | Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-10-28 | — | — | US | disclosed |
| US-6770644-B1 | Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| EP-1215203-A1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214896-A1 | Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient | HIF1AN, IL6, PYGM | FFAR1 872/4885ALDH1A1 274/4885POLB 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.